Tumor genome analysis includes germline genome: Are we ready for surprises?

International Journal of Cancer

Volumn 136, Issue 7, 2015, Pages 1559-1567

  Catenacci, Daniel V T ^a   Amico, Andrea L ^a   Nielsen, Sarah M ^a,b   Geynisman, Daniel M ^a   Rambo, Brittany ^a   Carey, George B ^a   Gulden, Cassandra ^a,b   Fackenthal, Jim ^a,b   Marsh, Robert D ^a   Kindler, Hedy L ^a   Olopade, Olufunmilayo I ^a,b  

^a SECTION OF HEMATOLOGY ONCOLOGY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Genetic counseling; Germline; Next generation sequencing; Somatic

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GENETICS; CANCER RISK; DIGESTIVE SYSTEM CANCER; DNA SEQUENCE; FAMILY COUNSELING; FEMALE; GENE IDENTIFICATION; GENE MUTATION; GENETIC SCREENING; GENOME ANALYSIS; GERMLINE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUTATIONAL ANALYSIS; PATIENT COUNSELING; RETROSPECTIVE STUDY; RISK ASSESSMENT; TUMOR SUPPRESSOR GENE; UNITED STATES; VERY ELDERLY; CHROMOSOME ABERRATION; EARLY CANCER DIAGNOSIS; FAMILY; GENETIC COUNSELING; GENETICS; GENOMICS; GERM CELL; HIGH THROUGHPUT SEQUENCING; METABOLISM; NEOPLASMS;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; EARLY DETECTION OF CANCER; FAMILY; FEMALE; GENETIC COUNSELING; GENETIC TESTING; GENOMICS; GERM CELLS; GERM-LINE MUTATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84920994909     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29128     Document Type: Article

References (28)

1. Macconaill LE. Existing and emerging technologies for tumor genomic profiling. J Clin Oncol 2013;31:1815-24. doi: 10.1200/JCO.2012.46.5948. Epub 2013 Apr 15.
2. Stricker T, Catenacci DV, Seiwert TY. Molecular profiling of cancer - the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic. Semin Oncol 2011;38:173-85.
3. Van Allen EM, Wagle N, Levy MA. Clinical analysis and interpretation of cancer genome data. J Clin Oncol 2013;31:1825-33. doi: 10.1200/JCO.2013.48.7215. Epub 2013 Apr 15.
4. Collins FS, Hamburg MA. First FDA authorization for next-generation sequencer. NEJM 2013;369:2369-71.
5. Domchek SM, Bradbury A, Garber JE, et al. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J Clin Oncol 2013;31:1267-70.
6. Lolkema MP, Gadellaa-van Hooijdonk CG, Bredenoord AL, et al. Ethical, legal, and counseling challenges surrounding the return of genetic results in oncology. J Clin Oncol 2013;31:1842-8. doi: 10.1200/JCO.2012.45.2789. Epub 2013 Apr 15.
7. Biesecker LG. Opportunities and challenges for the integration of massively parallel genomic sequencing into clinical practice: lessons from the ClinSeq project. Genet Med 2012;14:393-8.
8. Sleijfer S, Ballman K, Verweij J. The future of drug development? Seeking evidence of activity of novel drugs in small groups of patients. J Clin Oncol 2013;31:2246-8. doi: 10.1200/JCO.2013.48.7645. Epub 2013 Apr 29.
9. Tsimberidou AM, Iskander NG, Hong DS, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res 2012;18:6373-83.
10. Khoury J, Catenacci DV. Next-generation companion diagnostics: promises, challenges, and solutions. Arch Pathol Lab Med, in press.
11. Dienstmann R, Rodon J, Barretina J, et al. Genomic medicine frontier in human solid tumors: prospects and challenges. J Clin Oncol 2013;31:1874-84. doi: 10.1200/JCO.2012.45.2268. Epub 2013 Apr 15.
12. Garraway LA. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol 2013;31:1806-14. doi: 10.1200/JCO.2012.46.8934. Epub 2013 Apr 15.
13. Garraway LA, Verwey J, Ballman K. Precision oncology: an overview. J Clin Oncol 2013;31:1803-5. doi: 10.1200/JCO.2013.49.4799. Epub 2013 Apr 15.
14. Mendelsohn J. Personalizing oncology: perspectives and prospects. J Clin Oncol 2013;31:1904-11. doi: 10.1200/JCO.2012.45.3605. Epub 2013 Apr 15.
15. Gray SW, Hicks-Courant K, Lathan CS, et al. Attitudes of patients with cancer about personalized medicine and somatic genetic testing. J Oncol Pract 2012;8:329-35.
16. .www.foundationone.com.
17. Pritchard C, Smith C, Salipante S, et.al. ColoSeq provides comperhensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn 2012;14:357-366.
18. Walsh T, Lee M, Thornton A, et.al. Detection of inhereted mutations for breast and ovarian cancer using genomic cancer and massively parallel sequencing. PNAS 2010;107:12629-33.
19. Walsh T, Casadei S, Pennil C. et al. Mutations in 12 genes for inhereted ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. PNAS 2011;108:18033-37.
20. Robson ME, Storm CD, Weitzel J, et al. American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 2010;28:893-901.
21. Cybulski C, Wokolorczyk D, Jakubowska A, et al. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol 2011;29:3747-52.
22. Narod SA. Testing for CHEK2 in the cancer genetics clinic: ready for prime time? Clin Genet 2010;78:1-7.
23. Hampel H, Chapelle A. The search for unaffected individuals with lynch syndrome: do the ends justify the means? Cancer Prev Res (Phila) 2011;4:1-5.
24. Fitzgerald RC, Hardwick R, Huntsman D, et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 2010;47:436-44.
25. Meric-Bernstam F, Farhangfar C, Mendelsohn J, et al. Building a personalized medicine infrastructure at a major cancer center. J Clin Oncol 2013;31:1849-57. doi: 10.1200/JCO.2012.45.3043. Epub 2013 Apr 15.
26. Loud JT, Weissman NE, Peters JA, et al. Deliberate deceit of family members: a challenge to providers of clinical genetics services. J Clin Oncol 2006;24:1643-6.
27. Storm C, Agarwal R, Offit K. Ethical and legal implications of cancer genetic testing: do physicians have a duty to warn patients' relatives about possible genetic risks? J Oncol Pract 2008;4:229-30.
28. Patterson AR, Robinson LD, Naftalis EZ, et al. Custodianship of genetic information: clinical challenges and professional responsibility. J Clin Oncol 2005;23:2100-4.